Small molecule tracers binding to immune cell markers such as CD8, CD4, CD11b, or secreted proteins such as IFN-γ, IL-2, or TNF-α could be highly useful for characterizing the tumor immune landscape with a reduced wait time post-injection. This evidence concerns the gene CD4 and neoplasm.